IMAC Holdings Inc (BACK) Stock: What the Analysts are Saying

The stock has a 36-month beta value of 0.27. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for BACK is 1.62M, and at present, short sellers hold a 1.84% of that float. On September 24, 2024, the average trading volume of BACK was 129.60K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

BACK) stock’s latest price update

IMAC Holdings Inc (NASDAQ: BACK) has experienced a decline in its stock price by -17.05 compared to its previous closing price of 1.29. However, the company has seen a fall of -18.94% in its stock price over the last five trading days. globenewswire.com reported 2024-09-19 that Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) — IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of an entirely new precision oncology assay for breast cancer treatment decision making utilizing the Reverse Phase Protein Array (RPPA) technology through its newly established subsidiary, Ignite Proteomics LLC (“Ignite Proteomics”). This launch follows IMAC Holdings’ strategic acquisition of key assets from Theralink Technologies, Inc., and is underscored by a landmark clinical case study “ Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer”, demonstrating the power of RPPA technology in precision oncology published in npj Precision Oncology, an international, peer-reviewed journal focused on precision oncology.

BACK’s Market Performance

BACK’s stock has fallen by -18.94% in the past week, with a monthly drop of -40.88% and a quarterly drop of -58.37%. The volatility ratio for the week is 17.64% while the volatility levels for the last 30 days are 11.54% for IMAC Holdings Inc The simple moving average for the past 20 days is -30.97% for BACK’s stock, with a -51.38% simple moving average for the past 200 days.

BACK Trading at -34.90% from the 50-Day Moving Average

After a stumble in the market that brought BACK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.19% of loss for the given period.

Volatility was left at 11.54%, however, over the last 30 days, the volatility rate increased by 17.64%, as shares sank -38.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.12% lower at present.

During the last 5 trading sessions, BACK fell by -18.94%, which changed the moving average for the period of 200-days by -43.98% in comparison to the 20-day moving average, which settled at $1.5164. In addition, IMAC Holdings Inc saw -51.58% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for BACK

Current profitability levels for the company are sitting at:

  • 1.47 for the present operating margin
  • 3.37 for the gross margin

The net margin for IMAC Holdings Inc stands at 2.95. The total capital return value is set at 2.49. Equity return is now at value -237.34, with -131.01 for asset returns.

Currently, EBITDA for the company is -2.54 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of -0.87. The receivables turnover for the company is -2.86for trailing twelve months and the total asset turnover is -2.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.42.

Conclusion

To sum up, IMAC Holdings Inc (BACK) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts